New Data on 2-Drug HIV Regimen Top SPT Week in Review

5. New Clinical Data Further Support Efficacy of Nusinersen in Spinal Muscular Atrophy

Pre-symptomatic infants with spinal muscular atrophy treated with nusinersen showed continuous improvement in achieving motor milestones. Read more.
 

4. Three-Drug Combination Improves Survival for Patients with Advanced Colorectal Cancer

Data from the BEACON CRC trial show encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer. Read more.
 

3. BRCA1 Gene Leads to Better Understanding of Breast, Ovarian Cancer Development

In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent. Read more.
 

2. Remote-Controlled Drug Delivery Implant Can Improve Chronic Disease Management

A Bluetooth-enabled, nanochannel drug delivery system administers controlled doses based on patients’ therapeutic needs. Read more.
 

1. Dolutegravir/Lamivudine for HIV Non-Inferior to 3-Drug Regimen

Individuals with HIV maintained similar rates of viral suppression after switching from a 3-drug regimen to the 2-drug regimen of dolutegravir plus lamivudine. Read more.
 




Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Top news of the week from Specialty Pharmacy Times.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Top news of the week from Specialty Pharmacy Times.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$